PLUS1
Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Phio Pharmaceuticals Corporation | PHIO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.21 | -2.05% | 10.04 | 10.20 | 9.6425 | 10.20 | 10.25 | 09:52:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 9.85 | 10.01 | 0.16 | 1.6% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 76 | 3,529 | $ 9.92 | $ 35,012 | 47,605 | 0.097 - 10.57 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:59:37 | 7 | $ 10.01 | USD |
Phio Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 377.39M | 36.82M | $ -7.36M | -1.20 | 0.60 | 33.29M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Phio Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/10/2020 | 17:22 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/18/2019 | 07:30 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/13/2019 | 16:31 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) |
| 12/13/2019 | 08:01 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) |
| 12/06/2019 | 17:16 | Edgar (US Regulatory) | Amended Current Report Filing (8-k/a) |
| 11/22/2019 | 17:23 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) |
| 11/20/2019 | 06:02 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PHIO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.194 | 10.57 | 0.179 | 0.5088715 | 1,762,779 | 9.85 | 5,075.26% |
| 1 Month | 0.14 | 10.57 | 0.137 | 0.2444761 | 3,058,479 | 9.90 | 7,071.43% |
| 3 Months | 0.2499 | 10.57 | 0.097 | 0.1979704 | 1,839,518 | 9.79 | 3,917.61% |
| 6 Months | 0.40 | 10.57 | 0.097 | 0.2072812 | 915,465 | 9.64 | 2,410.0% |
| 1 Year | 0.345 | 10.57 | 0.097 | 0.2872579 | 709,914 | 9.70 | 2,810.14% |
| 3 Years | 0.39 | 10.57 | 0.097 | 0.2917331 | 665,935 | 9.65 | 2,474.36% |
| 5 Years | 0.39 | 10.57 | 0.097 | 0.2917331 | 665,935 | 9.65 | 2,474.36% |
Phio Pharmaceuticals Description
| Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immunooncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The clinical development program of the company includes RXI-109, a sd-rxRNA for the treatment of dermal and ocular scarring, and Samcyprone, for the treatment of warts. The pipeline product of the company includes RXI-109, Immuno-oncology cell therapy, samcyprone, RXI-231, and RXI-185. The pipeline programs focus on dermatology, including cosmetic product development, ophthalmology, and cell-based cancer immunotherapy. |
